Could cause temporary or reversible harm; serious harm is unlikely.
Lack of Assurance of Sterility: a recent FDA inspection at the manufacturing firm raised concerns that the product sterility may be compromised.
| Distributed by / for | Sandoz, Inc., Princeton, NJ |
| NDC | 66758-005-01 |
| Full product label | L-Cysteine Hydrochloride Injection, USP, 50 mg/mL, 50 mL Pharmacy Bulk Package Vials (NDC 66758-005-01), packaged in 5 x 50 mL Vials per carton(NDC 66758-005-02), Rx only, Manufactured for: Sandoz, Inc., Princeton, NJ. |
| Recalling firm | Sandoz Inc |
| Distribution | Nationwide throughout the USA |
| Quantity | 33,624 vials |
| Recall initiated | 2016-11-09 |
| Report date | 2016-11-23 |
| Recall completed | 2017-10-17 |
| Recall number | D-0141-2017 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Princeton NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗